Sibel Blau

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

Gabriel N. Hortobágyi, Salomon M. Stemmer, Howard A. Burris et al. · New England Journal of Medicine · 2016 · 1.9K citations · Full text

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Javier Cortés, David W. Cescon, Hope S. Rugo et al. · The Lancet · 2020 · 1.7K citations · Full text

Chemotherapy Versus Placebo, Breast Oncology, Oncology +7

Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA

Richard B. Lanman, Stefanie Mortimer, Oliver A. Zill et al. · PLoS ONE · 2015 · 708 citations · Full text

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Sung‐Bae Kim, Rebecca Dent, Seock‐Ah Im et al. · The Lancet Oncology · 2017 · 463 citations · Full text

First-line Therapy, Breast Oncology, Medicine +7

Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial

Angelo Di Leo, Stephen Johnston, Keun Seok Lee et al. · The Lancet Oncology · 2017 · 377 citations

Advanced Breast Cancer, Breast Oncology, Oncology +11